Affinity Asset Advisors LLC Has $131,000 Stake in Repare Therapeutics Inc. (NASDAQ:RPTX)

Affinity Asset Advisors LLC reduced its position in Repare Therapeutics Inc. (NASDAQ:RPTX) by 42.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,000 shares of the company’s stock after selling 73,351 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Repare Therapeutics were worth $131,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of RPTX. Stifel Financial Corp boosted its position in shares of Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after acquiring an additional 13,800 shares in the last quarter. Barclays PLC boosted its holdings in Repare Therapeutics by 1,471.7% during the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after purchasing an additional 7,800 shares in the last quarter. Vontobel Holding Ltd. grew its stake in shares of Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock valued at $46,000 after purchasing an additional 11,000 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock valued at $112,000 after purchasing an additional 85,798 shares during the period. Institutional investors and hedge funds own 85.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on RPTX shares. Bloom Burton lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th. HC Wainwright reduced their target price on shares of Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 7th.

Repare Therapeutics Price Performance

Shares of RPTX opened at $0.93 on Tuesday. The company has a market capitalization of $39.46 million, a P/E ratio of -0.46 and a beta of 0.91. The business’s 50 day simple moving average is $1.12 and its 200-day simple moving average is $2.01. Repare Therapeutics Inc. has a one year low of $0.89 and a one year high of $4.29.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. On average, sell-side analysts anticipate that Repare Therapeutics Inc. will post -2.04 EPS for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.